Magenta Therapeutics, Inc. — Form D
Magenta Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2017-05-05. The offering totals $50.0M, of which $46.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-05-05
- Form: D
- Accession: 0001690585-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $46.0M
- Remaining: $4.0M
- Investors: 13
- Date of first sale: 2017-04-21
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-286150
Issuer
- Name: Magenta Therapeutics, Inc.
- CIK: 0001690585
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 50 Hampshire Street, CAMBRIDGE, MA, 02139
- Phone: 857-242-0170
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Bastiano Sanna | Executive Officer | Cambridge, MA |
| Alexis Borisy | Director | Boston, MA |
| Bruce Booth | Director | Cambridge, MA |
| John Davis | Executive Officer | Dallas, TX |
| Blake Byers | Director | Menlo Park, CA |
| Jeffrey Albers | Director | Boston, MA |
| Michael Bonney | Director | Georgetown, ME |
| David Scadden | Director | Irvine, CA |
| Jason Gardner | Director | EMERYVILLE, CA |
| Jason Gardner | Executive Officer | EMERYVILLE, CA |
| Thomas Daniel | Director | San Francisco, CA |
| Zoran Zdraveski | Executive Officer | Cambridge, MA |
| Amy Ronneberg | Director | Cambridge, MA |
Other filings by this issuer (2)
More